Exploration of Side Effects and Patient-Reported Outcomes in First Line Compared to Late Line Chemotherapy and Targeted Therapies

With the advent of new therapies and more clinical trials, it is not uncommon for people with lung cancer to transition through multiple lines of therapy. However, how individuals feel and function during different treatment classes as well as first-line (1L) treatment compared to later treatments is poorly documented. This is due to limited real-world patient experience data linked with clinical data. Yet, patient experience data is a powerful tool in understanding the impacts of treatments and how these affect a person's quality of life (QoL).